Neuropathic pain (NeP) has been the focus of extensive basic and clinical research over the past 20 years. This has led to an increased understanding of underlying pathophysiological mechanisms and the development of new therapeutic agents, as well as a clearer definition of the role of established medications. To date there are no published treatment guidelines for NeP in the Middle East. A multidisciplinary panel of Middle East and international experts met to review critically and reach a consensus on how best to apply evidence-based guidelines for the treatment of NeP (mainly peripheral NeP) in the Middle East. The expert panel recommended pregabalin, gabapentin and secondary amine tricyclic antidepressants (nortriptyline and desipramine) as first-line treatments for peripheral NeP. Serotonin-norepinephrine reuptake inhibitor antidepressants, tramadol and controlled-release opioid analgesics were recommended as second-line treatments. There is a need to increase diagnostic awareness of NeP, use validated screening questionnaires and undertake more treatment research in the Middle East region.
TreedeRDJensenTSCampbellJN: Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology2008; 70: 1630–1635.
2.
FreynhagenRBennettMI: Diagnosis and management of neuropathic pain. BMJ2009; 339: 391–395.
3.
WiffenPJMcQuayHJMooreRA: Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev2005; Issue 3, Art No: CD005451, DOI: 10.1002/14651858. CD005451.
4.
WiffenPJMcQuayHJReesJ: Gabapentin for acute and chronic pain. Cochrane Database Syst Rev2005; Issue 3, Art No: CD005452, DOI: 10.1002/14651858.CD005452.
5.
ChalkCBensteadTJMooreF: Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev2007; Issue 4, Art No: CD004572, DOI: 10.1002/14651858.CD004572.pub2.
6.
EisenbergEMcNicolEDCarrDB: Opioids for neuropathic pain. Cochrane Database Syst Rev2006; Issue 3. Art No: CD006146, DOI: 10.1002/14651858.CD006146.
7.
SaartoTWiffenPJ: Antidepressants for neuropathic pain. Cochrane Database Syst Rev2007; Issue 4, Art No: CD005454, DOI: 10.1002/14651858.CD005454.pub2.
8.
WiffenPJReesJ: Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev2007; Issue 2, Art No: CD006044, DOI: 10.1002/14651858.CD006044.pub2.
9.
DuehmkeRMHollingsheadJCornblathDR: Tramadol for neuropathic pain. Cochrane Database Syst Rev2006; Issue 3, Art No: CD003726, DOI: 10.1002/14651858.CD003726. pub3.
10.
MooreRAStraubeSWiffenPJ: Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev2009; Issue 3, Art No: CD007076, DOI: 10.1002/14651858.CD007076.pub2.
11.
AttalNCruccuGHaanpääM: EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol2006; 13: 1153–1169.
MoulinDEClarkAJGilronI: Pharmacological management of chronic neuropathic pain–consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag2007; 12: 13–21.
14.
O'ConnorABDworkinRH: Treatment of neuropathic pain: An overview of recent guidelines. Am J Med2009; 12210 suppl): S22–S32.
15.
AcevedoJCAmayaACasasolaOde L: Guidelines for the diagnosis and management of neuropathic pain: Consensus of a group of Latin American experts. J Pain Palliat Care Pharmacother2009; 23: 261–281.
16.
GreenCRAndersonKOBakerTA: The unequal burden of pain: Confronting racial and ethnic disparities in pain. Pain Med2003; 4: 277–294.
17.
DanaeiGLawesCMVander HoornS: Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: Comparative risk assessment. Lancet2006; 368: 1651–1659.
18.
AbegundeDOMathersCDAdamT: The burden and costs of chronic diseases in low-income and middle-income countries. Lancet2007; 370: 1929–1938.
19.
SadoskyAMcDermottAMBrandenburgNA: A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract2008; 8: 45–56.
20.
Al-MahroosFAl-RoomiK: Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: A nationwide primary care diabetes clinic-based study. Ann Saudi Med2007; 27: 25–31.
21.
HalawaMRKarawaghAZeidanA: Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia. Curr Med Res Opin2010; 26: 337–343.
22.
HassanAESalehHABaroudyYM: Prevalence of neuropathic pain among patients suffering from chronic low back pain in Saudi Arabia. Saudi Med J2004; 25: 1986–1990.
23.
KakiAMEl-YaskiAZYouseifE: Identifying neuropathic pain among patients with chronic low-back pain: Use of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. Reg Anesth Pain Med2005; 30: 422–428.
24.
HoffmanDLSadoskyAAlvirJ: Cross-national burden of painful diabetic peripheral neuropathy in Asia, Latin America, and the Middle East. Pain Pract2009; 9: 35–42.
25.
ChenHLamerTJRhoRH: Contemporary management of neuropathic pain for the primary care physician. Mayo Clin Proc2004; 79: 1533–1545.
26.
SchappertSM: National Hospital Ambulatory Medical Care Survey: 1992 Emergency Department Summary. Vital Health Stat1997; 13 (125): 1–108.
27.
MäntyselkäPKumpusaloEAhonenR: Pain as a reason to visit the doctor: A study in Finnish primary health care. Pain2001; 89: 175–180.
28.
GurejeOVon KorffMSimonGE: Persistent pain and well-being: A World Health Organization Study in Primary Care. JAMA1998; 280: 147–151.
29.
MäntyselkäPKumpusaloEAhonenR: Patients’ versus general practitioners’ assessments of pain intensity in primary care patients with non-cancer pain. Br J Gen Pract2001; 51: 995–997.
30.
MerskeyHBogdukN (eds): Classification of Chronic Pain. Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd edn.Seattle: IASP Press, 1994.
31.
BouhassiraDAttalNAlchaarH: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain2005; 114: 29–36.
32.
FreynhagenRBaronRGockelU: painDETECT: A new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin2006; 22: 1911–1920.
33.
JunkerUFreynhagenRLänglerK: Paper versus electronic rating scales for pain assessment: A prospective, randomised, crossover validation study with 200 chronic pain patients. Curr Med Res Opin2008; 24: 1797–1806.
34.
KhawKMoreyraAETannenbaumAK: Improved detection of posterior myocardial wall ischemia with the 15-lead electrocardiogram. Am Heart J1999; 138: 934–940.
35.
NandaKMcCroryDCMyersER: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med2000; 132: 810–819.
36.
Portenoy R, for the ID Pain Steering Committee: Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin2006; 22: 1555–1565.
37.
FinnerupNBOttoMMcQuayHJ: Algorithm for neuropathic pain treatment: An evidence based proposal. Pain2005; 118: 289–305.
38.
DanzonPMEpsteinAJ: Effects of Regulation on Drug Launch and Pricing in Interdependent Markets. National Bureau of Economic Research (NBER) Working Paper No: 14041, May 2008.
39.
RascatiK (ed): Essentials of Pharmacoeconomics. Philadelphia: Lippincott Williams & Wilkins, 2008.
40.
McLellanRAOscarsonMSeidegårdJ: Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics1997; 7: 187–191.
41.
BradfordLD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics2002; 3: 229–243.
42.
Al-SarrajTSaadiHVolekJS: Metabolic syndrome prevalence, dietary intake, and cardiovascular risk profile among overweight and obese adults 18–50 years old from the United Arab Emirates. Metab Syndr Relat Disord2010; 8: 39–46.
43.
WeissmanMMBlandRCCaninoGJ: Cross-national epidemiology of major depression and bipolar disorder. JAMA1996; 276: 293–299.
44.
FramptonJEScottLJ: Pregabalin in the treatment of painful diabetic peripheral neuropathy. Drugs2004; 64: 2813–2820.
45.
RamakrishnanKScheidDC: Treatment options for insomnia. Am Fam Physician2007; 76: 517–526.
46.
SmithMTHaythornthwaiteJA: How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev2004; 8: 119–132.
47.
RowbothamMHardenNStaceyB: Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA1998; 280: 1837–1842.
48.
JensenMPChodroffMJDworkinRH: The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology2007; 68: 1178–1182.
49.
RodríguezMJDíazSVera-LlonchM: Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or postherpetic neuralgia. Curr Med Res Opin2007; 23: 2585–2596.
50.
TarrideJEGordonAVera-LlonchM: Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: A Canadian perspective. Clin Ther2006; 28: 1922–1934.
51.
RudorferMVPotterWZ: Metabolism of tricyclic antidepressants. Cell Mol Neurobiol1999; 19: 373–409.
52.
MooreARO'KeefeST: Drug-induced cognitive impairment in the elderly. Drugs Aging1999; 15: 15–28.
53.
MintzerJBurnsA: Anticholinergic side-effects of drugs in elderly people. J R Soc Med2000; 93: 457–462.
54.
SpinaEScordoMG: Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging2002; 19: 299–320.
55.
SommerBRFennHPompeiP: Safety of antidepressants in the elderly. Expert Opin Drug Saf2003; 2: 367–383.
SmithTNicholsonRA: Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag2007; 3: 833–844.
58.
WongICBesagFMSantoshPJ: Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf2004; 27: 991–1000.
59.
TiippanaEMHamunenKKontinenVK: Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. Anesth Analg2007; 104: 1545–1556.
60.
GilronIBaileyJMTuD: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med2005; 352: 1324–1334.
61.
GilronIBaileyJMTuD: Nortriptyline and gabapentin, alone and in combination for neuropathic pain: A double-blind, randomised controlled crossover trial. Lancet2009; 374: 1252–1261.
62.
FinnerupNB: A review of central neuropathic pain states. Curr Opin Anaesthesiol2008; 21: 586–589.
63.
GrayP: Pregabalin in the management of central neuropathic pain. Expert Opin Pharmacother2007; 8: 3035–3041.
64.
SiddallPJCousinsMJOtteA: Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial. Neurology2006; 67: 1792–1800.
65.
VrankenJHDijkgraafMGKruisMR: Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain2008; 136: 150–157.
66.
TzellosTGPapazisisGAmanitiE: Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: An evidence-based evaluation of the literature. Eur J Clin Pharmacol2008; 64: 851–858.
67.
RowbothamMCTwillingLDaviesPS: Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med2003; 348: 1223–1232.
68.
BockbraderHNRadulovicLLPosvarEL: Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol2010 (e-pub ahead of print: doi:10.1177/0091270009352087). The Journal of International Medical Research.
